Study Exclusion reasons Remarks Reference(s)
Gilboa, 2021 -

Gilboa M J Infect Dis 2021 Nov 29;jiab584. 10.1093/infdis/jiab584

 
UKHSA report 33 (23 december 2021), 2021 case control no usable date (only presented graphically without possibility to estimate values of CI limits)  
Musser, 2021 retrospective cohort

Musser JM et al. medrxiv;2021.07.19.21260808v1 10.1101/2021.07.19.21260808

 
UKHSA 31 december 2021, 2021 case control duplicate with Andrews 2021  
Rosenberg, 2021 retrospective cohort No Confidence Interval reported, not usable in meta-analysis

Rosenberg ES et al. MMWR Morb Mortal Wkly Rep 10.15585/mmwr.mm7034e1

 
Scobie, 2021 case control

Scobie HM et al. MMWR Morb Mortal Wkly Rep 10.15585/mmwr.mm7037e1

 
Southern California (Lewnard), 2022 retrospective cohort hospitalization rate among cases testing positive for SARS-CoV-2 infection : not a directly estimation of vaccine efficacy

Lewnard JA et al. medrxiv;2022.01.11.22269045v1 10.1101/2022.01.11.22269045

 
PHE variants (Technical briefing 12 22 may 2021), 2021 case control duplicate  
PHE (Stowe), 2021 retrospective cohort duplicate  
Candidate COVID-19 Vaccine (COV001), 2020 randomized controlled trial

Folegatti PM Lancet 2020 Aug 15;396(10249):467-478. 10.1016/S0140-6736(20)31604-4

 
PHE Technical briefing 16 (11/18 June 2021), 2021 retrospective cohort duplicte  
Babamahmoodi, 2021 observational study no control group

Babamahmoodi F et al. researchsquare 10.21203/rs.3.rs-709499/v1

 
Montgomery, 2021 retrospective cohort no control group

Montgomery J et al. JAMA Cardiol 10.1001/jamacardio.2021.2833

 
Barrett, 2020 - no control group phase 1/2

Barrett JR et al. Nat Med 10.1038/s41591-020-01179-4

 
Kawasuji, 2022 - no control group

Kawasuji H et al. medrxiv;2022.02.23.22271433v1 10.1101/2022.02.23.22271433

 
Falsey, 0 - no control group

Falsey AR et al. New England Journal of Medicine 10.1056/NEJMc2113468

 
NCT04276896, 0 single-arm no control group  
Ruddy, 2021 case series no control group

Ruddy JA AIDS 2021 Sep 1;35(11):1872-1874. 10.1097/QAD.0000000000002945

 
study 101 dose finding, 2020 non randomized controlled trial no control group phase 1

Anderson EJ N Engl J Med 2020 Sep 29. 10.1056/NEJMoa2028436

Jackson LA N Engl J Med 2020 Nov 12;383(20):1920-1931. 10.1056/NEJMoa2022483

 
Tobaiqy M, 2021 case series no control group retrospective descriptive study using spontaneous reports submitted to the EV database in the period from 17 February to 12 March 2021

Tobaiqy M Vaccines (Basel) 2021 Apr 16;9(4):393. 10.3390/vaccines9040393

 
Danza, 2022 case series no control group Omicron became the predominant SARS-CoV-2 variant in LAC during the week ending December 18, accounting for 57% of all sequenced specimens;Omicron prevalence continued to increase, accounting for 99% of all sequenced specimens for the week ending January 8, 2022

Danza P et al. MMWR Morb Mortal Wkly Rep 10.15585/mmwr.mm7105e1

 
BioNTech phase 2 (Walsh), 2020 randomized controlled trial no clinically relevant endpoint phase 1-2 ; dose-escalation : 13 groups of 15 participants  
Nanthapisal, 2022 randomized controlled trial no clinically relevant endpoint To evaluate immunogenicity and reactogenicity of standard- versus low-doseChAdOx1 nCoV-19 vaccine booster after CoronaVac in healthy adults

Nanthapisal S et al. medrxiv;2022.02.15.22270974v1 10.1101/2022.02.15.22270974

 
Liu, 2021 randomized controlled trial no clinically relevant endpoint

Liu J J Infect Dis 2021 Dec 27;jiab627. 10.1093/infdis/jiab627

 
COV-BOOST, 2021 randomized controlled trial no clinically relevant endpoint Phase 2 trial.

Munro APS Lancet 2021 Dec 2;S0140-6736(21)02717-3. 10.1016/S0140-6736(21)02717-3

 
UKHSA (report W4- 27 January), 2022 retrospective cohort (claims database) other study replaces by next report (Kiresbom et al)

Uk Health Security agency

 
Moderna preclinical (Corbett), 2020 randomized controlled trial other

Corbett KS N Engl J Med 2020 Oct 15;383(16):1544-1555. 10.1056/NEJMoa2024671

 
Pfizer 16-25 years phase 3, 0 randomized controlled trial other very preliminary results from a press release  
Ou, 2021 case series other safety and reactogenicity, no immunogenicity

Ou MT Transplantation 2021 Apr 9. 10.1097/TP.0000000000003780

 
Chen, 2021 randomized controlled trial other

Chen J Zhonghua Liu Xing Bing Xue Za Zhi 2021 Dec 10;42(12):2077-2081. 10.3760/cma.j.cn112338-20210807-00617

 
Mattiuzzi, 2022 - other same population alder study than mattiuzzi, 2022

Mattiuzzi C Eur Geriatr Med 2022 Jan 24. 10.1007/s41999-022-00615-7